Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

BackgroundEsophagogastric adenocarcinoma (EGA) presents a substantial global health challenge as the number of cases continues to rise. The current standard approach for treating localized EGA involves a combination of triplet chemotherapy, which consists of a platinum compound, a fluoropyrimidine,...

Full description

Bibliographic Details
Main Authors: Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, Thomas Ettrich, Thorsten Götze, Barbara Grün, Georg Martin Haag, Vera Heuer, Ralf-Dieter Hofheinz, Nils Homann, Tobias Sebastian Bröring, Mariana Santos Cruz, Annika Kurreck, Sylvie Lorenzen, Nicolas Moosmann, Christian Müller, Markus Schuler, Gabriele Siegler, Mascha Binder, Eray Gökkurt
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
esophagogastric adenocarcinoma
HER2
trastuzumab
pembrolizumab
perioperative
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1272175/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1272175/full

Similar Items